Joshua Schulman

Corporate Officer/Principal chez Joy Ventures

Profil

Josh is the Chief Scientist at Joy Ventures.
Before joining Joy, he led Partnerships and Innovation at Genetika+, a startup working on tools for successful drug development and personalized treatment of psychiatric disorders.
Prior to that, he led regulatory and clinical affairs at MaxQ AI and helped bring one of the first radiology AI applications to the market while working closely with FDA to develop policy on AI and Software as a Medical Device (SaMD).
He continues to be active in helping develop standards and policy for medical devices and has served on industry groups addressing the use artificial intelligence and cloud computing for healthcare.
For over a decade, Josh has also worked with academic technology transfer companies, small businesses, and investors across the medical device and pharma industries as well as lecturing and assisting team projects in Hebrew University’s Biodesign program.
Earlier in his career, Josh worked in both large and small pharmaceutical and medical device companies, including regulatory affairs at Omrix Biopharmaceuticals.
Josh’s scientific and management training began with a PhD in neuroscience which used magnetoencephalography to study the impact of different brain activity modes on normal and disease states.
Following a postdoc on brain biomarker development, he worked with government agencies on science strategy and program management.
Sources of Joy: Any activity with family

Postes actifs de Joshua Schulman

Sociétés	Poste	Début
Joy Ventures	Corporate Officer/Principal	01/05/2022

Anciens postes connus de Joshua Schulman

Sociétés	Poste	Fin
GenetikaPlus Ltd.	Private Equity Investor	01/04/2022
MaxQ AI Ltd.	Conseiller Juridique Général	01/04/2021
NeuroTech Solutions Ltd.	Directeur Technique/Scientifique/R&D	01/04/2016
Omrix Biopharmaceuticals Ltd.	Conseiller Juridique Général	01/09/2013
Firefly Neuroscience Ltd.	Corporate Officer/Principal	01/10/2009